New clinical trial for Juvia has started. Vaginitis is one of the most common gynecological problems in women. Candida albicans is responsible for more than 85% of vaginal fungal infections and reinfection after standard treatment is quite common. The aim of this study is to compare the effects of Juvia vaginal gel and oral fluconazole on the treatment and recurrence of vulvovaginal candidiasis (VVC). Our hypothesis is that Juvia vaginal gel may decrease the rate of reinfection after standard treatment with oral 150 mg fluconazole.